ATE178939T1 - Dna methyltransferase inhibierung - Google Patents

Dna methyltransferase inhibierung

Info

Publication number
ATE178939T1
ATE178939T1 AT95901306T AT95901306T ATE178939T1 AT E178939 T1 ATE178939 T1 AT E178939T1 AT 95901306 T AT95901306 T AT 95901306T AT 95901306 T AT95901306 T AT 95901306T AT E178939 T1 ATE178939 T1 AT E178939T1
Authority
AT
Austria
Prior art keywords
cell
demethylase
dna
level
dna methyltransferase
Prior art date
Application number
AT95901306T
Other languages
English (en)
Inventor
Moshe Szyf
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002110213A external-priority patent/CA2110213A1/en
Priority claimed from GB9413680A external-priority patent/GB9413680D0/en
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE178939T1 publication Critical patent/ATE178939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95901306T 1993-11-30 1994-11-30 Dna methyltransferase inhibierung ATE178939T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002110213A CA2110213A1 (en) 1993-11-30 1993-11-30 Inhibition of dna metase for therapy
GB9413680A GB9413680D0 (en) 1994-07-07 1994-07-07 Inhibition of tumorgenicity by inhibiting DNA methyltransferase activity

Publications (1)

Publication Number Publication Date
ATE178939T1 true ATE178939T1 (de) 1999-04-15

Family

ID=25676818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901306T ATE178939T1 (de) 1993-11-30 1994-11-30 Dna methyltransferase inhibierung

Country Status (9)

Country Link
US (1) US6184211B1 (de)
EP (3) EP1352956A1 (de)
JP (1) JPH09506253A (de)
KR (1) KR100392057B1 (de)
AT (1) ATE178939T1 (de)
AU (1) AU1061395A (de)
CA (1) CA2177031A1 (de)
DE (1) DE69417918T2 (de)
WO (1) WO1995015373A2 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652105A (en) * 1995-07-28 1997-07-29 Health Research, Inc. Substrate for detection of mammalian 5-C-DNA methyltransferase
EP0914324B1 (de) * 1996-05-22 2001-12-05 McGILL UNIVERSITY Spezifische inhibitoren vom dna-methyltransferaseenzym
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US7138384B1 (en) 1997-08-29 2006-11-21 The Regents Of The University Of California Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
US7098012B1 (en) * 1997-11-12 2006-08-29 Mcgill University DNA demethylase, therapeutic and diagnostic uses thereof
DE19754482A1 (de) * 1997-11-27 1999-07-01 Epigenomics Gmbh Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
CA2291367A1 (en) * 1999-12-06 2001-06-06 Isabelle Henry Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
DE10010282B4 (de) 2000-02-25 2006-11-16 Epigenomics Ag Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben
US20050282157A1 (en) 2000-04-06 2005-12-22 Alexander Olek Diagnosis of diseases associated with dna replication
US7384759B2 (en) * 2000-12-11 2008-06-10 The Salk Institute For Biological Studies Methods and compositions for determinig enzymatic activity and specificity of chalcone O-methyltransferases
EP1402071A4 (de) * 2001-06-08 2005-12-14 Us Genomics Inc Verfahren und produkte zur analyse von nukleinsäuren auf grundlage des methylierungsstatus
WO2003012051A2 (en) * 2001-07-31 2003-02-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Inhibitor of dna methylation
DE10154317B4 (de) 2001-10-26 2005-06-09 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierungen in immobilisierten DNA Proben
EP1340818A1 (de) 2002-02-27 2003-09-03 Epigenomics AG Verfahren und Nukleinsäuren zur Analyse von Kolonkrebszellen
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
ES2447566T3 (es) 2002-10-01 2014-03-12 Epigenomics Ag Uso de ácidos nucleicos de PITX2 para mejorar el tratamiento de trastornos proliferativos de células mamarias
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
AU2004252554B2 (en) 2003-06-23 2012-01-19 Epigenomics Ag Methods and nucleic acids for analyses of colorectal cell proliferative disorders
EP1636381B1 (de) 2003-06-23 2011-01-05 Epigenomics AG Verfahren und nukleinsäuren zur analyse von störungen der proliferation von kolonzellen
EP1636386B1 (de) 2003-06-23 2015-08-05 Epigenomics AG Verfahren und nukleinsäuren für analysen von störungen der proliferation von kolorektalzellen
US20050123944A1 (en) * 2003-08-01 2005-06-09 U.S. Genomics, Inc. Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions
CA2548528A1 (en) 2003-12-01 2005-06-16 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
DE602004031405D1 (de) 2003-12-11 2011-03-31 Epigenomics Ag Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
EP1778865A1 (de) 2004-06-23 2007-05-02 Epigenomics AG Verfahren und nukleinsäuren zum nachweis der metastasierung proliferativer kolonzellerkrankungen
EP2302073A1 (de) 2004-07-18 2011-03-30 Epigenomics AG Epigenetische Verfahren und Nukleinsäuren für den Nachweis von proliferativen Erkrankungen von Mammazellen
EP2213749A1 (de) 2004-12-02 2010-08-04 Epigenomics AG Verfahren und Nukleinsäuren zur Analyse von mit der Prognose von Störungen der Proliferation von Prostatazellen assoziierter Genexpression
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20060252723A1 (en) * 2005-04-01 2006-11-09 Methylgene, Inc. The Cleveland Clinic Foundation Combined therapy utilizing reduction of DNA methyltransferase expression and/or activity and interferon
EP1877577A2 (de) 2005-04-15 2008-01-16 Epigenomics Inc. Verfahren und nukleinsäuren für analysen zellulärer proliferativer störungen
EP1885884A2 (de) 2005-05-02 2008-02-13 University Of Southern California Mit cimp (cpg island methylator phenotype) bei humanem kolorektalkarzinom assoziierte dna-methylierungsmarker
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
EP1934369A2 (de) 2005-09-29 2008-06-25 Epigenomics AG Verfahren und nukleinsäuren zur analyse der mit gewebeklassifizierung assoziierten genexpression
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN101437933B (zh) 2005-12-28 2013-11-06 斯克里普斯研究所 作为药物靶标的天然反义和非编码的rna转录物
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
EP2013360A2 (de) 2006-04-17 2009-01-14 Epigenomics AG Verfahren und nukleinsäuren zum nachweis von proliferativen störungen kolorektaler zellen
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
US20100143902A1 (en) 2006-07-21 2010-06-10 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
EP2099938B1 (de) 2006-11-24 2016-11-16 Epigenomics AG Verfahren und nukleinsäuren zur analyse der mit der entwicklung von prostatazellproliferationsstörungen assoziierten genexpression
PL2258871T3 (pl) 2007-01-19 2014-10-31 Epigenomics Ag Sposoby i kwasy nukleinowe do analizy zaburzeń proliferacyjnych komórki
AU2008334901A1 (en) 2007-12-11 2009-06-18 Epigenomics Ag Methods and nucleic acids for analyses of lung carcinoma
EP2340244A4 (de) 2008-10-14 2012-07-25 Ning Xi Verbindungen und anwendungsverfahren
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
JP6091752B2 (ja) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
ES2560107T3 (es) 2009-02-12 2016-02-17 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
MX2011009752A (es) 2009-03-17 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
JP5944311B2 (ja) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
JP5907866B2 (ja) 2009-06-26 2016-04-26 クルナ・インコーポレーテッド ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
JP6013910B2 (ja) 2009-06-26 2016-10-25 エピゲノミクス アーゲー 膀胱細胞増殖性障害の分析のための方法及び核酸
CN102712925B (zh) 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN104313027B (zh) 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
EP2467482A4 (de) 2009-08-21 2013-12-11 Curna Inc Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
JP5964232B2 (ja) 2009-08-25 2016-08-03 カッパーアールエヌエー，インコーポレイテッド ‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
ES2664591T3 (es) 2009-09-25 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
US20110104695A1 (en) 2009-11-05 2011-05-05 Epigenomics Ag Methods of predicting therapeutic efficacy of cancer therapy
DK2513310T3 (en) 2009-12-16 2018-02-05 Curna Inc TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
ES2661387T3 (es) 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
EP2519634B1 (de) 2009-12-29 2016-06-01 CuRNA, Inc. Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
JP5993744B2 (ja) 2009-12-29 2016-09-14 カッパーアールエヌエー，インコーポレイテッド 核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR101854926B1 (ko) 2010-01-11 2018-05-04 큐알엔에이, 인크. 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
ES2671877T3 (es) 2010-01-25 2018-06-11 Curna, Inc. Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
ES2600356T3 (es) 2010-02-22 2017-02-08 Curna, Inc. Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
JP5978203B2 (ja) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
EP2957636B1 (de) 2010-05-03 2020-04-01 CuRNA, Inc. Behandlung von sirtuin 3 (sirt3)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt3
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
DK2585596T3 (da) 2010-06-23 2021-04-06 Curna Inc Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
CA2820709C (en) 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
ES2653247T3 (es) 2011-06-09 2018-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
PH12014500063A1 (en) 2011-07-08 2014-02-17 Epigenomics Ag Methods and nucleic acids for determining the prognosis of a cancer subject
CN103945902B (zh) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
MX365525B (es) 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
HUE040179T2 (hu) 2012-03-15 2019-02-28 Curna Inc Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
US8969388B1 (en) 2012-07-28 2015-03-03 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
KR102148681B1 (ko) 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
US10640808B2 (en) 2013-03-13 2020-05-05 Abbott Molecular Inc. Systems and methods for isolating nucleic acids
ES2712798T3 (es) 2013-03-14 2019-05-14 Exact Sciences Dev Co Llc Detección de neoplasias
EP2971171A4 (de) 2013-03-14 2016-11-02 Abbott Molecular Inc Multiplex-methylierungs-spezifische verstärkersysteme und -verfahren
WO2015124921A1 (en) 2014-02-19 2015-08-27 The University Court Of The University Of Edinburgh Methods and uses for determining the presence of inflammatory bowel disease
CN106460046A (zh) 2014-03-31 2017-02-22 梅奥医学教育和研究基金会 检测结直肠赘生物
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10465248B2 (en) 2014-12-12 2019-11-05 Exact Sciences Development Company, Llc Method of characterizing ZDHHC1 DNA
EP3274440B1 (de) 2015-03-27 2026-03-04 Exact Sciences Corporation Nachweis von erkrankungen der speiseröhre
EP3316685A4 (de) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen
WO2017040627A1 (en) 2015-08-31 2017-03-09 Mayo Foundation For Medical Education And Research Detecting gastric neoplasm
AU2016343517B2 (en) 2015-10-19 2020-04-30 Sunshine Lake Pharma Co., Ltd. A salt of EGFR inhibitor, crystalline form and uses thereof
WO2017075061A1 (en) 2015-10-30 2017-05-04 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of dna from plasma
KR20170050916A (ko) * 2015-11-02 2017-05-11 연세대학교 산학협력단 유전자 구조 내 CpG 섬의 후성 유전학적 변형을 통한 줄기세포의 분화 조절 방법
US10385406B2 (en) 2016-05-05 2019-08-20 Exact Sciences Development Company, Llc Detection of lung neoplasia by analysis of methylated DNA
CA3029842A1 (en) 2016-07-19 2018-01-25 Exact Sciences Development Company, Llc Methylated control dna
EP4293128A3 (de) 2016-09-02 2024-03-20 Mayo Foundation for Medical Education and Research Erkennung eines leberzellkarzinoms
WO2018140781A1 (en) 2017-01-27 2018-08-02 Exact Sciences Development Company, Llc Detection of colon neoplasia by analysis of methylated dna
KR102747156B1 (ko) 2017-02-28 2024-12-26 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 전립선 암의 검출
CN111182908A (zh) 2017-08-03 2020-05-19 大塚制药株式会社 药物化合物及其纯化方法
EP3717644A4 (de) 2017-11-30 2021-12-29 Mayo Foundation for Medical Education and Research Erkennung von brustkrebs
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
WO2020099938A2 (en) 2018-11-16 2020-05-22 Oslo Universitetssykehus Hf Methods and compositions for characterizing bladder cancer
CN111321210B (zh) * 2018-12-13 2021-09-14 贵阳优乐复生医学检验所有限公司 一种无创产前检测胎儿是否患有遗传疾病的方法
CA3127329A1 (en) 2019-01-24 2020-07-30 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
WO2021087275A1 (en) 2019-10-31 2021-05-06 Mayo Foundation For Medical Education And Research Detecting ovarian cancer
CN116670299A (zh) 2020-08-19 2023-08-29 梅约医学教育与研究基金会 检测非霍奇金淋巴瘤
CA3206781A1 (en) 2021-01-29 2022-08-04 John B. Kisiel Detecting the presence or absence of multiple types of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506944A4 (en) 1990-10-23 1994-08-17 Hope City Mechanism based inhibitors of dna methyltransferase
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6020318A (en) * 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides

Also Published As

Publication number Publication date
EP1352956A1 (de) 2003-10-15
CA2177031A1 (en) 1995-06-08
AU1061395A (en) 1995-06-19
US6184211B1 (en) 2001-02-06
EP0889122A2 (de) 1999-01-07
DE69417918D1 (de) 1999-05-20
DE69417918T2 (de) 2000-01-05
EP0889122A3 (de) 1999-03-03
EP0734436B1 (de) 1999-04-14
WO1995015373A3 (en) 1995-08-10
KR100392057B1 (ko) 2003-10-30
EP0734436A1 (de) 1996-10-02
WO1995015373A2 (en) 1995-06-08
JPH09506253A (ja) 1997-06-24

Similar Documents

Publication Publication Date Title
ATE178939T1 (de) Dna methyltransferase inhibierung
BR0010220A (pt) Compostos de pirimidinona
FI970768L (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä riippuvalla vaikuttavalla aineella
ATE184271T1 (de) Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren
DK0927150T3 (da) Lipoxinforbindelser og deres anvendelse til behandling af celleformeringsforstyrrelser
DK1280552T3 (da) Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor
PT1233958E (pt) Inibidores de histona desacetilase
NO20002127L (no) Terapeutiske aktive forbindelser basert pÕ indazol-bioster erstatning av catechol i PDE4 inhibitorer
BR9710801A (pt) Inibidores de purina de cinase 2 dependente deciclina e ikb-a
FI964958A7 (fi) Protoporfyrinogeenioksidaasientsyymin aktiivisuuden manipulointi eukaryoottisissa organismeissa
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
ATE309224T1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
GB2367555A (en) Control of gene expression
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
NO984462L (no) Sprayt°rkete mikropartikler som terapeutiske bµrere for bruk i genterapi
WO1998037185A3 (en) Vectors for controlled gene expression
TR199802649A2 (xx) Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri.
PT1002095E (pt) Estirpes melhoradas para expressao de proteinas
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
DE60120928D1 (de) Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung
UA81634C2 (ru) Фармацевтическая композиция уреазы для ингибирования роста раковых клеток и ее применение
PT986387E (pt) Inibidores de farnesil transferase em combinacao com inibidores de hmg coa redutase para o tratamento do cancro
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties